ORCHPHARMA — Orchid Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapSucker Stock

Annual income statement for Orchid Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	4,501	5,596	6,659	8,194	9,216
Cost of Revenue
Gross Profit	2,216	2,460	2,075	2,581	2,930
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	5,092	5,934	5,977	7,417	8,390
Operating Profit	-591	-339	682	776	827
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-952	-569	552	919	956
Provision for Income Taxes
Net Income After Taxes	-952	-569	552	951	958
Equity in Affiliates
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-1,165	-19.5	463	922	997
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-1,165	-19.5	463	922	997
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-23.3	-14.8	3.21	19.1	19.7